Results 21 to 30 of about 2,655 (208)

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience [PDF]

, 2023
Background Clinical trials and real-world studies revealed a spectrum of response to CGRP(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at all to total migraine freedom.
Fitzek, Mira, Overeem, Lucas H., Raffaelli, Bianca, Reuter, Uwe, Storch, Elisabeth, Terhart, Maria   +5 more
core   +1 more source

Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

BMC Neurology, 2020
Background Injection-site reactions have been reported with biologicals. In this post hoc analysis of Phase 3 studies in participants with migraine, we provide a comprehensive overview and detailed summary of injection-site reaction with galcanezumab ...
Virginia L. Stauffer, Shufang Wang, Jo Bonner, ByungKun Kim, Rohit Bhandari, Kathleen A. Day, Angelo Camporeale   +6 more
doaj   +1 more source

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis

BMC Neurology, 2022
Objective To evaluate the efficacy and safety of galcanezumab in patients with migraine in a real-world setting in Japan. Background Galcanezumab is the first anti-calcitonin gene-related peptide monoclonal antibody approved in Japan.
Tsubasa Takizawa, Seiya Ohtani, Narumi Watanabe, Naoki Miyazaki, Kei Ishizuchi, Koji Sekiguchi, Chisato Iba, Mamoru Shibata, Ryo Takemura, Satoko Hori, Jin Nakahara   +10 more
doaj   +1 more source

Clinical practice in prevention of migraine with calcitonin-gene related peptide monoclonal antibodies: real-world evidence [PDF]

, 2022
Introducción: Los anticuerpos monoclonales (mAbs) del péptido relacionado con el gen de la calcitonina (CGRP) son un novedoso tratamiento para prevenir la migraña crónica y la episódica de alta frecuencia.
Castaño-Amores, Celia, Nieto-Gómez, Pelayo, Nieto-Sánchez, María Teresa, Álvarez-Sánchez, Raquel   +3 more
core   +2 more sources

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies

BMC Neurology, 2020
Background Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days in phase 2 and 3 trials.
Mark E. Bangs, David Kudrow, Shufang Wang, Tina M. Oakes, Gisela M. Terwindt, Delphine Magis, Laura Yunes-Medina, Virginia L. Stauffer   +7 more
doaj   +1 more source

Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial

Neurology and Therapy, 2023
Introduction The efficacy and safety of galcanezumab as a preventive treatment in Japanese patients with episodic migraine was demonstrated in a phase 2, randomized, placebo-controlled trial (conducted December 2016–January 2019).
Mamoru Shibata, Atsuko Nihira, Yuka Tanji, Akichika Ozeki, Hideyuki Imagawa, Mika Komori   +5 more
doaj   +1 more source

Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

The Journal of Headache and Pain, 2022
Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials.
Bo Hu, Gang Li, Xiaohong Li, Shan Wu, Tingmin Yu, Xiang Li, Hongru Zhao, Zhihua Jia, Junpeng Zhuang, Shengyuan Yu   +9 more
doaj   +1 more source

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?

Frontiers in Neurology, 2023
ObjectiveTo report the efficacy of different anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) on headache frequency, intensity, and duration.BackgroundBlockade of CGRP receptors or neuropeptide with anti-CGRP mAbs have been ...
Sena Uzun, Sena Uzun, Ulf Frejvall, Gülsen Özkaya-Sahin, Gülsen Özkaya-Sahin, Gürdal Sahin, Gürdal Sahin   +6 more
doaj   +1 more source

Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario [PDF]

, 2023
Objectives: Migraine is a neurological disease with a high frequency of incidence. The new monoclonal antibodies selective for the calcitonin gene-related peptide and its ligand (anti-CGRP mAbs) have been marketed both in the USA and EU based on the ...
Ferrara, Francesco, Langella, Roberto, Lasala, Ruggero, Musazzi, Umberto Maria, Sabbatucci, Michela, Vitiello, Antonio, Zovi, Andrea   +6 more
core   +1 more source

Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies [PDF]

, 2021
Background Migraine preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs) has a positive effect on patients' health-related quality of life (HRQoL).
Mecklenburg, Jasper, Neeb, Lars, Overeem, Lucas Hendrik, Raffaelli, Bianca, Reuter, Uwe, Siebert, Anke, Steinicke, Maureen, Terhart, Maria   +7 more
core   +1 more source